Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  2/10/2014
Oregon Center for Clinical Investigations, Inc.
mi
from
Portland, OR
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 2/10/2014
Oregon Center for Clinical Investigations, Inc.
mi
from
Portland, OR
Click here to add this to my saved trials
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  2/10/2014
Oregon Center for Clinical Investigations, Inc
mi
from
Salem, OR
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 2/10/2014
Oregon Center for Clinical Investigations, Inc
mi
from
Salem, OR
Click here to add this to my saved trials
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  2/10/2014
Thomas Wind
mi
from
West Chester, PA
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 2/10/2014
Thomas Wind
mi
from
West Chester, PA
Click here to add this to my saved trials
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  2/10/2014
Richard Ohnmacht
mi
from
Warwick, RI
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 2/10/2014
Richard Ohnmacht
mi
from
Warwick, RI
Click here to add this to my saved trials
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  2/10/2014
Abraham Moskow
mi
from
Barnwell, SC
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 2/10/2014
Abraham Moskow
mi
from
Barnwell, SC
Click here to add this to my saved trials
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  2/10/2014
Research Across America/Psychiatric Medical Associates
mi
from
Dallas, TX
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 2/10/2014
Research Across America/Psychiatric Medical Associates
mi
from
Dallas, TX
Click here to add this to my saved trials
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  2/10/2014
Michael Downing
mi
from
Dallas, TX
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 2/10/2014
Michael Downing
mi
from
Dallas, TX
Click here to add this to my saved trials
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  2/10/2014
Clinical Trial Network
mi
from
Houston, TX
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 2/10/2014
Clinical Trial Network
mi
from
Houston, TX
Click here to add this to my saved trials
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  2/10/2014
Claghorn-Lesem Research Clinic
mi
from
Houston, TX
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 2/10/2014
Claghorn-Lesem Research Clinic
mi
from
Houston, TX
Click here to add this to my saved trials
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  2/10/2014
Texas Center for Drug Development, P.A.
mi
from
Houston, TX
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 2/10/2014
Texas Center for Drug Development, P.A.
mi
from
Houston, TX
Click here to add this to my saved trials
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  2/10/2014
Houston Clinical Trials, LLC
mi
from
Houston, TX
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 2/10/2014
Houston Clinical Trials, LLC
mi
from
Houston, TX
Click here to add this to my saved trials
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  2/10/2014
Bayou City Research, Ltd.
mi
from
Houston, TX
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 2/10/2014
Bayou City Research, Ltd.
mi
from
Houston, TX
Click here to add this to my saved trials
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  2/10/2014
Red Oak Psychiatry Associates, PA
mi
from
Houston, TX
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 2/10/2014
Red Oak Psychiatry Associates, PA
mi
from
Houston, TX
Click here to add this to my saved trials
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  2/10/2014
R/D Clinical Research, Inc.
mi
from
Lake Jackson, TX
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 2/10/2014
R/D Clinical Research, Inc.
mi
from
Lake Jackson, TX
Click here to add this to my saved trials
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  2/10/2014
Westex Clinical Investigations
mi
from
Lubbock, TX
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 2/10/2014
Westex Clinical Investigations
mi
from
Lubbock, TX
Click here to add this to my saved trials
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  2/10/2014
Tracy Schillerstrom
mi
from
San Antonio, TX
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 2/10/2014
Tracy Schillerstrom
mi
from
San Antonio, TX
Click here to add this to my saved trials
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  2/10/2014
University of Texas Health Science Center at San Antonio
mi
from
San Antonio, TX
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 2/10/2014
University of Texas Health Science Center at San Antonio
mi
from
San Antonio, TX
Click here to add this to my saved trials
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  2/10/2014
Marshall Lucas
mi
from
The Woodlands, TX
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 2/10/2014
Marshall Lucas
mi
from
The Woodlands, TX
Click here to add this to my saved trials
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  2/10/2014
Ericksen Research and Development - Westside Medical
mi
from
Clinton, UT
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 2/10/2014
Ericksen Research and Development - Westside Medical
mi
from
Clinton, UT
Click here to add this to my saved trials
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  2/10/2014
University of Virginia Child and Family Psychiatry Clinic
mi
from
Charlottesville, VA
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 2/10/2014
University of Virginia Child and Family Psychiatry Clinic
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  2/10/2014
Northwest Clinical Research Center
mi
from
Bellevue, WA
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 2/10/2014
Northwest Clinical Research Center
mi
from
Bellevue, WA
Click here to add this to my saved trials
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  2/10/2014
James Knutson
mi
from
Kirkland, WA
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 2/10/2014
James Knutson
mi
from
Kirkland, WA
Click here to add this to my saved trials
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  2/10/2014
Summit Research Network (Seattle) LLC
mi
from
Seattle, WA
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 2/10/2014
Summit Research Network (Seattle) LLC
mi
from
Seattle, WA
Click here to add this to my saved trials
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  2/10/2014
Rockwood Clinic, PS
mi
from
Spokane, WA
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 2/10/2014
Rockwood Clinic, PS
mi
from
Spokane, WA
Click here to add this to my saved trials
Studying the Effects of Copaxone on Retinal Health Using Optical Tomography Over 24 Months
A Prospective, Observational, Single-blinded, Longitudinal Optical Coherence Tomography Study of Effect of Copaxone (Glatiramer Acetate) on Retinal Nerve Fiber Layer Thickness in Patients With Relapsing-remitting Multiple Sclerosis Over 24 Months
Status: Enrolling
Updated:  2/11/2014
Buffalo Neuroimaging Analysis Center
mi
from
Buffalo, NY
Studying the Effects of Copaxone on Retinal Health Using Optical Tomography Over 24 Months
A Prospective, Observational, Single-blinded, Longitudinal Optical Coherence Tomography Study of Effect of Copaxone (Glatiramer Acetate) on Retinal Nerve Fiber Layer Thickness in Patients With Relapsing-remitting Multiple Sclerosis Over 24 Months
Status: Enrolling
Updated: 2/11/2014
Buffalo Neuroimaging Analysis Center
mi
from
Buffalo, NY
Click here to add this to my saved trials
The Biomechanical Effects of Flaccid Paralysis Induced by Botulinum Toxin a After Damage Control Laparotomy
The Biomechanical Effects of Flaccid Paralysis Induced by Botulinum Toxin a After Damage Control Laparotomy: A Pilot Study
Status: Enrolling
Updated:  2/12/2014
Mayo Clinic Rochester
mi
from
Rochester, MN
The Biomechanical Effects of Flaccid Paralysis Induced by Botulinum Toxin a After Damage Control Laparotomy
The Biomechanical Effects of Flaccid Paralysis Induced by Botulinum Toxin a After Damage Control Laparotomy: A Pilot Study
Status: Enrolling
Updated: 2/12/2014
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
A Study to Evaluate the Incidence of Hypersensitivity After Administration of Sugammadex in Healthy Participants (MK-8616-101)
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Incidence of Hypersensitivity After Repeated Single Dose Administration of Sugammadex (MK-8616) in Healthy Subjects
Status: Enrolling
Updated:  2/12/2014
Clinical Research Facility
mi
from
Tempe, AZ
A Study to Evaluate the Incidence of Hypersensitivity After Administration of Sugammadex in Healthy Participants (MK-8616-101)
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Incidence of Hypersensitivity After Repeated Single Dose Administration of Sugammadex (MK-8616) in Healthy Subjects
Status: Enrolling
Updated: 2/12/2014
Clinical Research Facility
mi
from
Tempe, AZ
Click here to add this to my saved trials
A Study to Evaluate the Incidence of Hypersensitivity After Administration of Sugammadex in Healthy Participants (MK-8616-101)
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Incidence of Hypersensitivity After Repeated Single Dose Administration of Sugammadex (MK-8616) in Healthy Subjects
Status: Enrolling
Updated:  2/12/2014
Clinical Research Facility
mi
from
South Miami, FL
A Study to Evaluate the Incidence of Hypersensitivity After Administration of Sugammadex in Healthy Participants (MK-8616-101)
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Incidence of Hypersensitivity After Repeated Single Dose Administration of Sugammadex (MK-8616) in Healthy Subjects
Status: Enrolling
Updated: 2/12/2014
Clinical Research Facility
mi
from
South Miami, FL
Click here to add this to my saved trials
A Study to Evaluate the Incidence of Hypersensitivity After Administration of Sugammadex in Healthy Participants (MK-8616-101)
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Incidence of Hypersensitivity After Repeated Single Dose Administration of Sugammadex (MK-8616) in Healthy Subjects
Status: Enrolling
Updated:  2/12/2014
Clinical Research Facility
mi
from
Lincoln, NE
A Study to Evaluate the Incidence of Hypersensitivity After Administration of Sugammadex in Healthy Participants (MK-8616-101)
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Incidence of Hypersensitivity After Repeated Single Dose Administration of Sugammadex (MK-8616) in Healthy Subjects
Status: Enrolling
Updated: 2/12/2014
Clinical Research Facility
mi
from
Lincoln, NE
Click here to add this to my saved trials
A Study to Evaluate the Incidence of Hypersensitivity After Administration of Sugammadex in Healthy Participants (MK-8616-101)
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Incidence of Hypersensitivity After Repeated Single Dose Administration of Sugammadex (MK-8616) in Healthy Subjects
Status: Enrolling
Updated:  2/12/2014
Clinical Research Facility
mi
from
San Antonio, TX
A Study to Evaluate the Incidence of Hypersensitivity After Administration of Sugammadex in Healthy Participants (MK-8616-101)
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Incidence of Hypersensitivity After Repeated Single Dose Administration of Sugammadex (MK-8616) in Healthy Subjects
Status: Enrolling
Updated: 2/12/2014
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Ampyra for Optic Neuritis in MS
Dalfampridine After Optic Neuritis to Improve Visual Function in Multiple Sclerosis
Status: Enrolling
Updated:  2/14/2014
Washington University (John L. Trotter MS Center)
mi
from
St. Louis, MO
Ampyra for Optic Neuritis in MS
Dalfampridine After Optic Neuritis to Improve Visual Function in Multiple Sclerosis
Status: Enrolling
Updated: 2/14/2014
Washington University (John L. Trotter MS Center)
mi
from
St. Louis, MO
Click here to add this to my saved trials
Walnut Oral Immunotherapy for Tree Nut Allergy
Walnut Oral Immunotherapy for Tree Nut Allergy-CHOP
Status: Enrolling
Updated:  2/19/2014
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Walnut Oral Immunotherapy for Tree Nut Allergy
Walnut Oral Immunotherapy for Tree Nut Allergy-CHOP
Status: Enrolling
Updated: 2/19/2014
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Acupuncture for Sexual Dysfunction
Acupuncture in Premenopausal Women With Hypoactive Sexual Desire Disorder: A Prospective Cohort
Status: Enrolling
Updated:  2/20/2014
TriHealth, Inc
mi
from
Cincinnati, OH
Acupuncture for Sexual Dysfunction
Acupuncture in Premenopausal Women With Hypoactive Sexual Desire Disorder: A Prospective Cohort
Status: Enrolling
Updated: 2/20/2014
TriHealth, Inc
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Vilazodone for Corticosteroid-Induced Memory Impairment
Vilazodone for Corticosteroid-Induced Memory Impairment
Status: Enrolling
Updated:  2/21/2014
U.T. Southwestern Medical Center
mi
from
Dallas, TX
Vilazodone for Corticosteroid-Induced Memory Impairment
Vilazodone for Corticosteroid-Induced Memory Impairment
Status: Enrolling
Updated: 2/21/2014
U.T. Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Non-Invasive Brain Signal Training to Induce Motor Control Recovery After Stroke
Non-Invasive Brain Signal Training to Induce Motor Control Recovery After Stroke
Status: Enrolling
Updated:  2/23/2014
Malcom Randall VA Medical Center
mi
from
Gainesville, FL
Non-Invasive Brain Signal Training to Induce Motor Control Recovery After Stroke
Non-Invasive Brain Signal Training to Induce Motor Control Recovery After Stroke
Status: Enrolling
Updated: 2/23/2014
Malcom Randall VA Medical Center
mi
from
Gainesville, FL
Click here to add this to my saved trials
Expiratory Muscle Conditioning in Multiple Sclerosis Using Magnetic Stimulation
Cleveland Clinic Research Program: Expiratory Muscle Conditioning Using Functional Magnetic Stimulation for Patients With Multiple Sclerosis
Status: Enrolling
Updated:  2/26/2014
Cleveland Clinic
mi
from
Cleveland, OH
Expiratory Muscle Conditioning in Multiple Sclerosis Using Magnetic Stimulation
Cleveland Clinic Research Program: Expiratory Muscle Conditioning Using Functional Magnetic Stimulation for Patients With Multiple Sclerosis
Status: Enrolling
Updated: 2/26/2014
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
An Open-label Safety, Tolerability and Dose-range Finding Study of Multiple Doses of ISIS SMNRx in Patient With Spinal Muscular Atrophy
An Open-Label, Dose Escalation Study to Assess the Safety, Tolerability and Dose-Range Finding of Multiple Doses of ISIS 396443 Delivered Intrathecally to Patients With Spinal Muscular Atrophy
Status: Enrolling
Updated:  3/3/2014
Boston Children's Hospital
mi
from
Boston, MA
An Open-label Safety, Tolerability and Dose-range Finding Study of Multiple Doses of ISIS SMNRx in Patient With Spinal Muscular Atrophy
An Open-Label, Dose Escalation Study to Assess the Safety, Tolerability and Dose-Range Finding of Multiple Doses of ISIS 396443 Delivered Intrathecally to Patients With Spinal Muscular Atrophy
Status: Enrolling
Updated: 3/3/2014
Boston Children's Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
An Open-label Safety, Tolerability and Dose-range Finding Study of Multiple Doses of ISIS SMNRx in Patient With Spinal Muscular Atrophy
An Open-Label, Dose Escalation Study to Assess the Safety, Tolerability and Dose-Range Finding of Multiple Doses of ISIS 396443 Delivered Intrathecally to Patients With Spinal Muscular Atrophy
Status: Enrolling
Updated:  3/3/2014
Columbia University Medical Center
mi
from
New York, NY
An Open-label Safety, Tolerability and Dose-range Finding Study of Multiple Doses of ISIS SMNRx in Patient With Spinal Muscular Atrophy
An Open-Label, Dose Escalation Study to Assess the Safety, Tolerability and Dose-Range Finding of Multiple Doses of ISIS 396443 Delivered Intrathecally to Patients With Spinal Muscular Atrophy
Status: Enrolling
Updated: 3/3/2014
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
An Open-label Safety, Tolerability and Dose-range Finding Study of Multiple Doses of ISIS SMNRx in Patient With Spinal Muscular Atrophy
An Open-Label, Dose Escalation Study to Assess the Safety, Tolerability and Dose-Range Finding of Multiple Doses of ISIS 396443 Delivered Intrathecally to Patients With Spinal Muscular Atrophy
Status: Enrolling
Updated:  3/3/2014
UT Southwestern Medical Center - Children's Medical Center Dallas
mi
from
Dallas, TX
An Open-label Safety, Tolerability and Dose-range Finding Study of Multiple Doses of ISIS SMNRx in Patient With Spinal Muscular Atrophy
An Open-Label, Dose Escalation Study to Assess the Safety, Tolerability and Dose-Range Finding of Multiple Doses of ISIS 396443 Delivered Intrathecally to Patients With Spinal Muscular Atrophy
Status: Enrolling
Updated: 3/3/2014
UT Southwestern Medical Center - Children's Medical Center Dallas
mi
from
Dallas, TX
Click here to add this to my saved trials
An Open-label Safety, Tolerability and Dose-range Finding Study of Multiple Doses of ISIS SMNRx in Patient With Spinal Muscular Atrophy
An Open-Label, Dose Escalation Study to Assess the Safety, Tolerability and Dose-Range Finding of Multiple Doses of ISIS 396443 Delivered Intrathecally to Patients With Spinal Muscular Atrophy
Status: Enrolling
Updated:  3/3/2014
University of Utah School of Medicine
mi
from
Salt Lake City, UT
An Open-label Safety, Tolerability and Dose-range Finding Study of Multiple Doses of ISIS SMNRx in Patient With Spinal Muscular Atrophy
An Open-Label, Dose Escalation Study to Assess the Safety, Tolerability and Dose-Range Finding of Multiple Doses of ISIS 396443 Delivered Intrathecally to Patients With Spinal Muscular Atrophy
Status: Enrolling
Updated: 3/3/2014
University of Utah School of Medicine
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Neuromuscular Ultrasound in ALS
Ultrasonography in Amyotrophic Lateral Sclerosis as a Predictor of Disease Progression and Tool in Diagnosis: a Pilot Study
Status: Enrolling
Updated:  3/3/2014
Duke Univ Med Ctr
mi
from
Durham, NC
Neuromuscular Ultrasound in ALS
Ultrasonography in Amyotrophic Lateral Sclerosis as a Predictor of Disease Progression and Tool in Diagnosis: a Pilot Study
Status: Enrolling
Updated: 3/3/2014
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Extracellular Signal-Related Kinase Biomarker Development in Autism
Extracellular Signal-Related Kinase Biomarker Development in Autism
Status: Enrolling
Updated:  3/5/2014
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Extracellular Signal-Related Kinase Biomarker Development in Autism
Extracellular Signal-Related Kinase Biomarker Development in Autism
Status: Enrolling
Updated: 3/5/2014
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Systemic Normothermia in Intracerebral Hemorrhage (ICH)
Systemic Normothermia in Intracerebral Hemorrhage (ICH)
Status: Enrolling
Updated:  3/5/2014
Cleveland Clinic
mi
from
Cleveland, OH
Systemic Normothermia in Intracerebral Hemorrhage (ICH)
Systemic Normothermia in Intracerebral Hemorrhage (ICH)
Status: Enrolling
Updated: 3/5/2014
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
Pilot Study of Riluzole for Drug-Refractory Irritability in Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Pilot Study of Riluzole for Drug-Refractory Irritability in Autism Spectrum Disorders
Status: Enrolling
Updated:  3/5/2014
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Pilot Study of Riluzole for Drug-Refractory Irritability in Autism Spectrum Disorders
A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Pilot Study of Riluzole for Drug-Refractory Irritability in Autism Spectrum Disorders
Status: Enrolling
Updated: 3/5/2014
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated:  3/6/2014
Collaborative Neuroscience Network, Inc.
mi
from
Long Beach, CA
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated: 3/6/2014
Collaborative Neuroscience Network, Inc.
mi
from
Long Beach, CA
Click here to add this to my saved trials
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated:  3/6/2014
University of California, Davis Medical Center
mi
from
Sacramento, CA
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated: 3/6/2014
University of California, Davis Medical Center
mi
from
Sacramento, CA
Click here to add this to my saved trials
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated:  3/6/2014
University of California at San Francisco (UCSF)
mi
from
San Francisco, CA
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated: 3/6/2014
University of California at San Francisco (UCSF)
mi
from
San Francisco, CA
Click here to add this to my saved trials
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated:  3/6/2014
Stanford Univ Med Ctr
mi
from
Stanford, CA
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated: 3/6/2014
Stanford Univ Med Ctr
mi
from
Stanford, CA
Click here to add this to my saved trials
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated:  3/6/2014
University of Colorado Denver
mi
from
Aurora, CO
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated: 3/6/2014
University of Colorado Denver
mi
from
Aurora, CO
Click here to add this to my saved trials
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated:  3/6/2014
IMMUNOe
mi
from
Centennial, CO
An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis
A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)
Status: Enrolling
Updated: 3/6/2014
IMMUNOe
mi
from
Centennial, CO
Click here to add this to my saved trials